Farmaforum 2026 | QbD Group

Event details

Farmaforum 2026 celebrates its twelfth edition in Madrid. Over eleven years, Farmaforum has established itself as the most important event for the pharmaceutical industry in Spain, expanding its scope to adjacent sectors such as medical devices, biotech, veterinary and more. The congress brings together manufacturers, service providers, regulators and researchers for two days of exhibitions, workshops and networking at IFEMA.

QbD Group, your life sciences partner across the entire product lifecycle

Stop by booth H08 at Farmaforum 2026 to meet our team and discover how QbD Group can support your projects across pharma, biotech and medical devices. Join us for two hands-on workshops led by our experts:

Workshop 1 — Digital Maturity in Pharma: the roadmap toward AI-ready pharmaceutical manufacturing

When: Monday 22 September 2026, 11:00–12:00

The digital transformation of pharmaceutical manufacturing does not start with AI: it starts on the shop floor. This one-hour workshop walks through the stages of digital maturity from an operations and manufacturing perspective: how to digitalize production processes, manage shop-floor data, and evolve the systems validation approach (from CSV to CSA) to build a connected, future-ready manufacturing environment. Beyond technology, the session addresses the changes in operating models, processes, and culture that determine whether a plant can truly capitalize on digitalization. Attendees will gain practical insights into how progress along this maturity path translates into greater agility, operational excellence, quality performance, and faster innovation, and into a solid foundation on which AI can deliver value in manufacturing.

Workshop 2 — Navigating FDA Inspections in the Age of Annex 1: From Warning Letters to Remediation Excellence

When: Tuesday 23 September 2026, 12:00–14:00

Aseptic manufacturing remains under significant regulatory scrutiny, with FDA inspections and enforcement actions continuing to highlight recurring vulnerabilities in sterile manufacturing operations, quality systems and contamination control strategies. At the same time, EU GMP Annex 1 has reinforced expectations around proactive risk management, process understanding and sustained contamination control.

This workshop provides a practical perspective on how selected FDA inspection outcomes and Warning Letter findings can be used to strengthen inspection readiness and remediation strategies in sterile manufacturing environments. The session explores recurring themes observed in aseptic processing and quality oversight, and how these findings can be translated into meaningful actions such as improved investigations, stronger CAPA, enhanced governance and more robust remediation plans.

Book a meeting with our team

Our Spanish business development team will be on-site throughout Farmaforum 2026. Book a one-to-one meeting in advance or drop by booth H08 to discuss your regulatory, quality, manufacturing or digital transformation needs.

Laia Cruz